UCBJY News and Press, UCB S.A. ADR From 02/20/20

The following slide deck was published by UCB SA in conjunction with their 2019 Q4 earnings Read more ...

Amgen (NASDAQ: AMGN ) and UCB ( OTCPK:UCBJY ) announces that the European Commission (EC) has granted marketing authorization for EVENITY (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. More news on: Amgen Inc., UCB SA, UCB SA...

-  New survey reveals that 65% of women with osteoporosis believe their condition is being neglected 1 -  58% said that the impact of osteoporosis/fragility fractures is not fully understood or appreciated by their healthcare authority , with four in five (83%) agreeing that t...

THOUSAND OAKS, Calif. and BRUSSELS , Dec. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Commission (EC) has granted marketing authorization for EVENITY ® (romosozumab) for the treatment of severe osteoporosis i...

- Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy d...

BRUSSELS , Dec. 6, 2019 /PRNewswire/ --  Regulated Information – Inside Information  – UCB, a global biopharmaceutical company, today announced positive results from the Phase 3 active-controlled BE SURE study. BE SURE compared the investigational IL-17A and IL-...

ATLANTA , Dec. 5, 2019 /PRNewswire/ -- UCB today announced 14 posters have been selected for presentation at this year's American Epilepsy Society Meeting, taking place in Baltimore, Maryland , December 6-10 . The UCB scientific program includes the presentation of clinical data de...

ATLANTA , Nov. 25, 2019 /PRNewswire/ -- UCB announced today that NAYZILAM® (midazolam) nasal spray CIV will be available in retail pharmacies on December 2, 2019 , for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acu...

BRUSSELS , Nov. 15, 2019 /PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from BE READY, the second of three Phase 3 studies this year to report findings on the investigational tre...

BRUSSELS , Nov. 8, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced important new rheumatology data being presented on CIMZIA ® (certolizumab pegol) and investigational molecules bimekizumab and dapirolizumab pegol at the 2019 American College of Rheumat...